LON:PRTC - PureTech Health Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 153 0.00 (0.00 %)
(As of 05/21/2018 04:00 PM ET)
Previous CloseGBX 153
Today's RangeGBX 150 - GBX 159.50
52-Week RangeGBX 111.50 - GBX 183.50
Volume90,241 shs
Average Volume71,917 shs
Market Capitalization£379.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About PureTech Health (LON:PRTC)

PureTech Health logoPureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Receive PRTC News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolLON:PRTC
CUSIPN/A
Phone+1-617-4822333

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-10,126.32%
Return on Equity-53.32%
Return on Assets-47.28%

Miscellaneous

EmployeesN/A
Outstanding Shares237,430,000

PureTech Health (LON:PRTC) Frequently Asked Questions

What is PureTech Health's stock symbol?

PureTech Health trades on the London Stock Exchange (LON) under the ticker symbol "PRTC."

What price target have analysts set for PRTC?

5 analysts have issued 1 year price objectives for PureTech Health's shares. Their forecasts range from GBX 245 to GBX 313. On average, they anticipate PureTech Health's share price to reach GBX 266.25 in the next twelve months. View Analyst Ratings for PureTech Health.

Who are PureTech Health's key executives?

PureTech Health's management team includes the folowing people:
  • Ms. Daphne Zohar, Founder, CEO & Exec. Director (Age 47)
  • Dr. Bennett M. Shapiro, Co-Founder & Non-Exec. Director (Age 78)
  • Dr. Robert S. Langer Jr., Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 69)
  • Mr. Stephen M. Muniz J.D., COO, Exec. VP of Legal & Operations, Sec. and Exec. Director (Age 48)
  • Dr. Bharatt M. Chowrira, Pres and Chief of Bus. & Strategy (Age 53)

Has PureTech Health been receiving favorable news coverage?

News coverage about PRTC stock has been trending somewhat positive on Monday, Accern reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PureTech Health earned a media sentiment score of 0.09 on Accern's scale. They also assigned press coverage about the company an impact score of 47.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of PureTech Health?

Shares of PRTC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is PureTech Health's stock price today?

One share of PRTC stock can currently be purchased for approximately GBX 153.

How big of a company is PureTech Health?

PureTech Health has a market capitalization of £379.89 million.

How can I contact PureTech Health?

PureTech Health's mailing address is 501 Boylston St Ste 6102, BOSTON, MA 02116-3769, United States. The company can be reached via phone at +1-617-4822333.


MarketBeat Community Rating for PureTech Health (PRTC)

Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  322 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  403
MarketBeat's community ratings are surveys of what our community members think about PureTech Health and other stocks. Vote "Outperform" if you believe PRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PureTech Health (LON:PRTC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for PureTech Health in the last 12 months. Their average twelve-month price target is GBX 266.25The high price target for PRTC is GBX 313 and the low price target for PRTC is GBX 245. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 266.25GBX 260.20GBX 260.20GBX 242.80

PureTech Health (LON:PRTC) Consensus Price Target History

Price Target History for PureTech Health (LON:PRTC)

PureTech Health (LON:PRTC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/9/2018Jefferies GroupReiterated RatingBuyGBX 245View Rating Details
5/9/2018Peel HuntReiterated RatingBuyGBX 313View Rating Details
4/16/2018Liberum CapitalReiterated RatingBuyGBX 248View Rating Details
3/2/2018N+1 SingerReiterated RatingBuyView Rating Details
2/20/2018Numis SecuritiesReiterated RatingBuyGBX 259View Rating Details
(Data available from 5/21/2016 forward)

Earnings

Dividends

PureTech Health (LON:PRTC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

PureTech Health (LON PRTC) Insider Trading and Institutional Ownership History

Insider Trading History for PureTech Health (LON:PRTC)

PureTech Health (LON PRTC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Robert LangerInsiderBuy4,300GBX 162£6,966
4/28/2016Scardino,Dame MarjorieInsiderBuy5,000GBX 135£6,750
10/26/2015Ito,JoichiInsiderBuy6,650GBX 149£9,908.50
10/9/2015Scardino,MarjorieInsiderBuy6,890GBX 126£8,681.40
9/28/2015Langer,RobertInsiderBuy7,200GBX 135£9,720
9/16/2015LaMattina,JohnInsiderBuy11,000GBX 146£16,060
9/10/2015LaMattina,JohnInsiderBuy5,492GBX 146£8,018.32
9/9/2015LaMattina,JohnInsiderBuy11,000GBX 147£16,170
9/4/2015LaMattina,JohnInsiderBuy11,000GBX 138£15,180
9/3/2015Scardino,MarjorieInsiderBuy10,000GBX 135£13,500
(Data available from 1/1/2013 forward)

Headlines

PureTech Health (LON PRTC) News Headlines

Source:
DateHeadline
PureTech Health (PRTC) Earns "Buy" Rating from Peel HuntPureTech Health (PRTC) Earns "Buy" Rating from Peel Hunt
www.americanbankingnews.com - May 9 at 6:57 PM
Akili Completes $55 Million Financing to Advance Company’s Digital Medicine Platform and Product Pipeline Aimed at Treating Cognitive DysfunctionAkili Completes $55 Million Financing to Advance Company’s Digital Medicine Platform and Product Pipeline Aimed at Treating Cognitive Dysfunction
finance.yahoo.com - May 9 at 10:08 AM
PureTech Healths (PRTC) Buy Rating Reiterated at Jefferies GroupPureTech Health's (PRTC) Buy Rating Reiterated at Jefferies Group
www.americanbankingnews.com - May 9 at 6:36 AM
Sonde Health Appoints Thai Lee to Board of DirectorsSonde Health Appoints Thai Lee to Board of Directors
finance.yahoo.com - May 2 at 9:58 AM
PureTech Health Appoints Joep Muijrers as Chief Financial OfficerPureTech Health Appoints Joep Muijrers as Chief Financial Officer
finance.yahoo.com - April 24 at 10:01 AM
PureTech Health (PRTC) Rating Reiterated by Liberum CapitalPureTech Health (PRTC) Rating Reiterated by Liberum Capital
www.americanbankingnews.com - April 18 at 10:16 PM
PureTech Health (PRTC) Stock Rating Reaffirmed by Liberum CapitalPureTech Health (PRTC) Stock Rating Reaffirmed by Liberum Capital
www.americanbankingnews.com - April 16 at 7:11 AM
Akili Digital Medicine Technology Platform Granted Multiple PatentsAkili Digital Medicine Technology Platform Granted Multiple Patents
finance.yahoo.com - April 10 at 10:33 AM
PureTech Ventures (PRTC) "Buy" Rating Reiterated at Peel HuntPureTech Ventures' (PRTC) "Buy" Rating Reiterated at Peel Hunt
www.americanbankingnews.com - April 9 at 8:06 PM
Commense Appoints Edward J. “Tad” Stewart as President and Chief Executive OfficerCommense Appoints Edward J. “Tad” Stewart as President and Chief Executive Officer
finance.yahoo.com - April 9 at 10:25 AM
PureTech Ventures (PRTC) Earns Buy Rating from Liberum CapitalPureTech Ventures (PRTC) Earns Buy Rating from Liberum Capital
www.americanbankingnews.com - April 8 at 8:36 PM
PureTech Ventures (PRTC) "Buy" Rating Reaffirmed at Peel HuntPureTech Ventures' (PRTC) "Buy" Rating Reaffirmed at Peel Hunt
www.americanbankingnews.com - April 8 at 8:36 PM
PureTech Ventures (PRTC) Buy Rating Reaffirmed at Peel HuntPureTech Ventures' (PRTC) Buy Rating Reaffirmed at Peel Hunt
www.americanbankingnews.com - April 4 at 12:31 PM
PureTech Ventures (PRTC) Rating Reiterated by Peel HuntPureTech Ventures (PRTC) Rating Reiterated by Peel Hunt
www.americanbankingnews.com - April 3 at 10:30 PM
Alivio Technology for Treating Inflammatory Diseases via Targeted Disease Immunomodulation Published in Nature CommunicationsAlivio Technology for Treating Inflammatory Diseases via Targeted Disease Immunomodulation Published in Nature Communications
finance.yahoo.com - April 3 at 3:56 PM
Puretech Health (PRTC) Receives Buy Rating from Peel HuntPuretech Health (PRTC) Receives Buy Rating from Peel Hunt
www.americanbankingnews.com - April 1 at 9:48 PM
Puretech Healths (PRTC) Buy Rating Reaffirmed at Peel HuntPuretech Health's (PRTC) Buy Rating Reaffirmed at Peel Hunt
www.americanbankingnews.com - March 31 at 1:00 PM
Puretech Health (PRTC) Receives "Buy" Rating from Peel HuntPuretech Health (PRTC) Receives "Buy" Rating from Peel Hunt
www.americanbankingnews.com - March 26 at 12:04 AM
Puretech Health (PRTC) Earns "Buy" Rating from Numis SecuritiesPuretech Health (PRTC) Earns "Buy" Rating from Numis Securities
www.americanbankingnews.com - March 25 at 10:58 AM
Puretech Health (PRTC) Earns Buy Rating from Liberum CapitalPuretech Health (PRTC) Earns Buy Rating from Liberum Capital
www.americanbankingnews.com - March 24 at 3:22 PM
Puretech Health (PRTC) Given "Buy" Rating at Liberum CapitalPuretech Health (PRTC) Given "Buy" Rating at Liberum Capital
www.americanbankingnews.com - March 18 at 2:45 PM
Puretech Health PLC (PRTC) Insider Purchases £6,966 in StockPuretech Health PLC (PRTC) Insider Purchases £6,966 in Stock
www.americanbankingnews.com - March 14 at 7:28 AM
PureTech Health Completes USD100 Million Discounted Share Placing (ALLISS)PureTech Health Completes USD100 Million Discounted Share Placing (ALLISS)
www.morningstar.co.uk - March 13 at 10:45 AM
BRIEF-Puretech Health To Raise $100 Million Via Accelerated BookbuildingBRIEF-Puretech Health To Raise $100 Million Via Accelerated Bookbuilding
www.reuters.com - March 13 at 10:45 AM
Is PureTech Health plc’s (LON:PRTC) Balance Sheet Strong Enough To Weather A Storm?Is PureTech Health plc’s (LON:PRTC) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - March 6 at 4:18 PM
Puretech Health (PRTC) Stock Rating Reaffirmed by N+1 SingerPuretech Health (PRTC) Stock Rating Reaffirmed by N+1 Singer
www.americanbankingnews.com - March 3 at 10:34 PM
Gelesis Raises $30 Million to Prepare for Potential Launch of Lead ProductGelesis Raises $30 Million to Prepare for Potential Launch of Lead Product
finance.yahoo.com - March 1 at 9:50 AM
Peel Hunt Reiterates Buy Rating for Puretech Health (PRTC)Peel Hunt Reiterates Buy Rating for Puretech Health (PRTC)
www.americanbankingnews.com - February 20 at 6:58 AM
Numis Securities Reiterates "Buy" Rating for Puretech Health (PRTC)Numis Securities Reiterates "Buy" Rating for Puretech Health (PRTC)
www.americanbankingnews.com - January 29 at 9:06 AM
Peel Hunt Increases Puretech Health (PRTC) Price Target to GBX 313Peel Hunt Increases Puretech Health (PRTC) Price Target to GBX 313
www.americanbankingnews.com - January 27 at 12:36 PM
Puretech Healths (PRTC) Buy Rating Reiterated at Liberum CapitalPuretech Health's (PRTC) Buy Rating Reiterated at Liberum Capital
www.americanbankingnews.com - January 27 at 12:36 PM
resTORbio Appoints Lynne Sullivan to Its Board of DirectorsresTORbio Appoints Lynne Sullivan to Its Board of Directors
finance.yahoo.com - January 3 at 9:34 AM
Puretech Health (PRTC) Earns Buy Rating from Peel HuntPuretech Health (PRTC) Earns Buy Rating from Peel Hunt
www.americanbankingnews.com - December 24 at 3:26 PM
Vedanta Biosciences Granted Four New U.S. Patents Expanding ... - Business Wire (press release)Vedanta Biosciences Granted Four New U.S. Patents Expanding ... - Business Wire (press release)
www.businesswire.com - December 13 at 4:46 PM
resTORbio Appoints Paul Fonteyne to Its Board of DirectorsresTORbio Appoints Paul Fonteyne to Its Board of Directors
finance.yahoo.com - December 11 at 11:01 AM
Why your doctor may soon have you playing video gamesWhy your doctor may soon have you playing video games
finance.yahoo.com - December 5 at 12:01 PM
PureTech Health Plc breached its 50 day moving average in a Bullish Manner : PRTC-GB : December 4, 2017PureTech Health Plc breached its 50 day moving average in a Bullish Manner : PRTC-GB : December 4, 2017
finance.yahoo.com - December 4 at 10:19 AM
Puretech Healths (PRTC) Buy Rating Reiterated at Peel HuntPuretech Health's (PRTC) Buy Rating Reiterated at Peel Hunt
www.americanbankingnews.com - December 1 at 12:28 AM
Puretech Healths (PRTC) "Buy" Rating Reiterated at N+1 SingerPuretech Health's (PRTC) "Buy" Rating Reiterated at N+1 Singer
www.americanbankingnews.com - November 30 at 11:02 PM
Liberum Capital Reiterates Buy Rating for Puretech Health (PRTC)Liberum Capital Reiterates Buy Rating for Puretech Health (PRTC)
www.americanbankingnews.com - November 30 at 9:42 PM
Numis Securities Raises Puretech Health (PRTC) Price Target to GBX 233Numis Securities Raises Puretech Health (PRTC) Price Target to GBX 233
www.americanbankingnews.com - November 30 at 7:34 PM
Peel Hunt Reiterates Buy Rating for Puretech Health PLC (PRTC)Peel Hunt Reiterates Buy Rating for Puretech Health PLC (PRTC)
www.americanbankingnews.com - November 21 at 12:16 AM
Puretech Health PLC (PRTC) Receives "Buy" Rating from Jefferies Group LLCPuretech Health PLC (PRTC) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - November 18 at 1:38 PM
Should You Buy PureTech Health plc (LSE:PRTC)?Should You Buy PureTech Health plc (LSE:PRTC)?
finance.yahoo.com - November 18 at 11:03 AM
PureTech Health to Present at Jefferies 2017 Healthcare Conference in LondonPureTech Health to Present at Jefferies 2017 Healthcare Conference in London
finance.yahoo.com - November 9 at 11:57 AM
Vedanta Biosciences Awarded Up To $5.4 Million from CARB-X to Accelerate Development of VE303, a Novel Human ... - Business Wire (press release)Vedanta Biosciences Awarded Up To $5.4 Million from CARB-X to Accelerate Development of VE303, a Novel Human ... - Business Wire (press release)
www.businesswire.com - November 4 at 9:05 AM
Vedanta Biosciences Awarded Up To $5.4 Million from CARB-X to Accelerate Development of VE303, a Novel Human Microbiome-Derived Treatment for Serious Bacterial InfectionVedanta Biosciences Awarded Up To $5.4 Million from CARB-X to Accelerate Development of VE303, a Novel Human Microbiome-Derived Treatment for Serious Bacterial Infection
finance.yahoo.com - November 4 at 9:05 AM
Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live ... - Business Wire (press release)Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live ... - Business Wire (press release)
www.businesswire.com - November 1 at 7:42 AM
Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live Biotherapeutics that Induce CD8+ T CellsVedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live Biotherapeutics that Induce CD8+ T Cells
finance.yahoo.com - November 1 at 7:42 AM
PureTech Health plc (LSE:PRTC): How Does It Impact Your Portfolio?PureTech Health plc (LSE:PRTC): How Does It Impact Your Portfolio?
finance.yahoo.com - October 3 at 11:06 AM

SEC Filings

PureTech Health (LON:PRTC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

PureTech Health (LON PRTC) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.